Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies

References

• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26(1):83–97.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009;24(3):133–138.
   PubMed Web of Science ®Google Scholar
• Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188–e196.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64.
   PubMed Web of Science ®Google Scholar
• Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(Suppl 1):S29–S37.
   PubMedGoogle Scholar
• Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–1231.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–1240.
   PubMed Web of Science ®Google Scholar
• Hobart M, Skuban A, Zhang P, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4):17m12058.
   PubMed Web of Science ®Google Scholar
• Hobart M, Skuban A, Zhang P, et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34(4):633–642.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed text revision. Washington (DC): American Psychiatric Association; 2000.
   Google Scholar
• Chandler GM, Iosifescu DV, Pollack MH, et al. Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–296.
   PubMedGoogle Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): National Institute of Mental Health; 1976.
   Google Scholar
• Bech P, Tanghøj P, Andersen HF, et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002;163(1):20–25.
   PubMed Web of Science ®Google Scholar
• Rexulti® (brexpiprazole) tablets, for oral use. Prescribing information; 2018 [ cited 2019 Apr 26]. Available from: https://www.otsuka-us.com/media/static/Rexulti-PI.pdf
   Google Scholar
• Duru G, Fantino B. The clinical relevance of changes in the Montgomery–Åsberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329–1335.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24(3):111–118.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
   Google Scholar
• Nelson JC, Weiller E, Zhang P, et al. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: a post hoc analysis of two pooled clinical studies. J Affect Disord. 2018;227:103–108.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord. 2010;120(1–3):133–140.
   PubMed Web of Science ®Google Scholar
• Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451–462.
   PubMed Web of Science ®Google Scholar
• Thase ME, Weiller E, Zhang P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2018;15:37–45.
   PubMed Web of Science ®Google Scholar
• Fava M, Weiller E, Zhang P, et al. Efficacy of brexpiprazole as adjunctive treatment in major depressive disorder with irritability: post hoc analysis of 2 pivotal clinical studies. J Clin Psychopharmacol. 2017;37(2):276–278.
   PubMed Web of Science ®Google Scholar
• Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016;6(10):e00520.
   PubMed Web of Science ®Google Scholar
• Fava M, Ménard F, Davidsen CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry. 2016;77(12):1695–1701.
   PubMed Web of Science ®Google Scholar
• Krystal AD, Mittoux A, Meisels P, et al. Effects of adjunctive brexpiprazole on sleep disturbances in patients with major depressive disorder: an open-label, flexible-dose, exploratory study. Prim Care Companion CNS Disord. 2016;18(5). DOI:10.4088/PCC.15m01914
   PubMedGoogle Scholar
• Lepola U, Hefting N, Zhang D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability study. Int J Geriatr Psychiatry. 2018;33(10):1403–1410.
   PubMed Web of Science ®Google Scholar
• Hobart M, Zhang P, Weiss C, et al. Adjunctive brexpiprazole and functioning in major depressive disorder: a pooled analysis of six randomized studies using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019;22(3):173–179.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Ota A, Tsuneyoshi K, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016;204:40–47.
   PubMed Web of Science ®Google Scholar
• Hobart M, Zhang P, Skuban A, et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. J Clin Psychopharmacol. 2019;39(3):203–209.
   PubMed Web of Science ®Google Scholar
• Bauer M, Hefting N, Lindsten A, et al. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. Acta Neuropsychiatr. 2019;31(1):27–35.
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411.
   PubMed Web of Science ®Google Scholar
• Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–147.
   PubMed Web of Science ®Google Scholar